Patents associated with high-cost drugs in Australia.

Article English OPEN
Andrew F Christie; Chris Dent; Peter McIntyre; Lachlan Wilson; David M Studdert;
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE,volume 8,issue 4 (issn: 1932-6203, eissn: 1932-6203)
  • Related identifiers: pmc: PMC3618270, doi: 10.1371/journal.pone.0060812
  • Subject: Social and Behavioral Sciences | Research Article | Drug Licensing and Regulation | Law | Medicine | Health Care Policy | Drug Research and Development | Drug Policy | Q | R | Drugs and Devices | Drug Discovery | Science | Commercial Law | Public Health | Non-Clinical Medicine | Health Economics
    mesheuropmc: health care economics and organizations

Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by “evergreening” blockbuster drugs, through misuse of the patent system. There is,... View more
Share - Bookmark